Cargando…
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma pa...
Ejemplares similares
-
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
por: Passamonti, Francesco, et al.
Publicado: (2021) -
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
por: Passamonti, Francesco, et al.
Publicado: (2020) -
Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV
por: Zappasodi, Patrizia, et al.
Publicado: (2022) -
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi
por: Merli, Michele, et al.
Publicado: (2022) -
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2021)